Abstract
DARPP-32 is a dual-function protein kinase/phosphatase inhibitor that is involved in striatal signaling. The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the effects of both psychostimulant and antipsychotic drugs; however, these drugs are known to have opposing behavioral and clinical effects. We hypothesized that these drugs exert differential effects on striatonigral and striatopallidal neurons, which comprise distinct output pathways of the basal ganglia. To directly test this idea, we developed bacterial artificial chromosome transgenic mice that allowed the analysis of DARPP-32 phosphorylation selectively in striatonigral and striatopallidal neurons. Using this new methodology, we found that cocaine, a psychostimulant, and haloperidol, a sedation-producing antipsychotic, exert differential effects on DARPP-32 phosphorylation in the two neuronal populations that can explain their opposing behavioral effects. Furthermore, we found that a variety of drugs that target the striatum have cell type–specific effects that previous methods were not able to discern.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Greengard, P. The neurobiology of slow synaptic transmission. Science 294, 1024–1030 (2001).
Greengard, P., Allen, P.B. & Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435–447 (1999).
Nishi, A. et al. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA 97, 12840–12845 (2000).
Ahn, J.H. et al. Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56δ subunit. Proc. Natl. Acad. Sci. USA 104, 2979–2984 (2007).
Bibb, J.A. et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons. Nature 402, 669–671 (1999).
Svenningsson, P. et al. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269–296 (2004).
Zachariou, V. et al. Phosphorylation of DARPP-32 at threonine 34 is required for cocaine action. Neuropsychopharmacology 31, 555–562 (2006).
Zhang, Y. et al. Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32. J. Neurosci. 26, 2645–2651 (2006).
Hakansson, K. et al. Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. J. Neurochem. 96, 482–488 (2006).
Gerfen, C.R. et al. D1 and D2 dopamine receptor–regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429–1432 (1990).
Missale, C., Nash, S.R., Robinson, S.W., Jaber, M. & Caron, M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78, 189–225 (1998).
Stoof, J.C. & Kebabian, J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294, 366–368 (1981).
Albin, R.L., Young, A.B. & Penney, J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366–375 (1989).
Fink, J.S. et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186–195 (1992).
Nishi, A., Snyder, G.L. & Greengard, P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147–8155 (1997).
Pothos, E.N., Przedborski, S., Davila, V., Schmitz, Y. & Sulzer, D. D2-like dopamine autoreceptor activation reduces quantal size in PC12 cells. J. Neurosci. 18, 5575–5585 (1998).
Schmitz, Y., Schmauss, C. & Sulzer, D. Altered dopamine release and uptake kinetics in mice lacking D2 receptors. J. Neurosci. 22, 8002–8009 (2002).
Miyamoto, S., Duncan, G.E., Marx, C.E. & Lieberman, J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005).
Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A. & Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51, 83–133 (1999).
Svenningsson, P., Le Moine, C., Fisone, G. & Fredholm, B.B. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 59, 355–396 (1999).
Lindskog, M. et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature 418, 774–778 (2002).
Nestler, E.J. Molecular basis of long-term plasticity underlying addiction. Nat. Rev. Neurosci. 2, 119–128 (2001).
Yan, Z. et al. Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin. Nat. Neurosci. 2, 13–17 (1999).
Pozzi, L. et al. Opposite regulation by typical and atypical antipsychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum. J. Neurochem. 86, 451–459 (2003).
Svenningsson, P. et al. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84, 223–228 (1998).
Farde, L. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49, 538–544 (1992).
Jin, L.Q., Wang, H.Y. & Friedman, E. Stimulated D(1) dopamine receptors couple to multiple Galpha proteins in different brain regions. J. Neurochem. 78, 981–990 (2001).
Voorn, P., Vanderschuren, L.J., Groenewegen, H.J., Robbins, T.W. & Pennartz, C.M. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 27, 468–474 (2004).
Nishi, A. et al. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc. Natl. Acad. Sci. USA 102, 1199–1204 (2005).
Cameron, D.L. & Williams, J.T. Dopamine D1 receptors facilitate transmitter release. Nature 366, 344–347 (1993).
Le Moine, C., Svenningsson, P., Fredholm, B.B. & Bloch, B. Dopamine-adenosine interactions in the striatum and the globus pallidus: inhibition of striatopallidal neurons through either D2 or A2A receptors enhances D1 receptor–mediated effects on c-fos expression. J. Neurosci. 17, 8038–8048 (1997).
Day, M. et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9, 251–259 (2006).
Lee, K.W. et al. Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor–containing medium spiny neurons in nucleus accumbens. Proc. Natl. Acad. Sci. USA 103, 3399–3404 (2006).
Ade, K.K., Janssen, M.J., Ortinski, P.I. & Vicini, S. Differential tonic GABA conductances in striatal medium spiny neurons. J. Neurosci. 28, 1185–1197 (2008).
Gong, S., Yang, X.W., Li, C. & Heintz, N. Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res. 12, 1992–1998 (2002).
Svenningsson, P. et al. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J. Comp. Neurol. 399, 229–240 (1998).
Valjent, E. et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. USA 102, 491–496 (2005).
Hemmings, H.C. Jr. & Greengard, P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate–regulated phosphoprotein: regional, tissue and phylogenetic distribution. J. Neurosci. 6, 1469–1481 (1986).
Acknowledgements
This work was funded by US National Institutes of Health grants MH074866 and DA10044, the Picower Foundation, the Simons Foundation, the Peter J. Sharp Foundation, US Department of Health and Human Services Administration on Aging grant 90AZ2791 and Department of Defense/US Army Medical Research Acquisition Activity grants DAMD17-02-1-0705 and W81XWH-05-1-0146.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figure 1 and Supplementary Methods (PDF 102 kb)
Rights and permissions
About this article
Cite this article
Bateup, H., Svenningsson, P., Kuroiwa, M. et al. Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11, 932–939 (2008). https://doi.org/10.1038/nn.2153
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn.2153
This article is cited by
-
The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents
Archives of Pharmacal Research (2024)
-
Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential
Cellular and Molecular Neurobiology (2023)
-
Microfluidics delivery of DARPP-32 into HeLa cells maintains viability for in-cell NMR spectroscopy
Communications Biology (2022)
-
Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns
Psychopharmacology (2021)
-
Cocaine-mediated circadian reprogramming in the striatum through dopamine D2R and PPARγ activation
Nature Communications (2020)